Primary hyperhidrosis of the axillae

Indication for Botulinum toxin type A

Population group: Suitable for both men and women, only adults (18 years old or older)
Therapeutic intent: Curative procedure

Botulinum toxin type A is indicated for the management of severe hyperhidrosis of the axillae, which does not respond to topical treatment with antiperspirants or antihidrotics.

For this indication, competent medicine agencies globally authorize below treatments:

50 Units to each axilla once every 16 weeks

For: Adults (18-64) Elders (65+)

Dosage regimens

Intradermal, 50 international units, once every 16 weeks.

Detailed description

Recommended needle: Sterile 30 gauge needle.

Administration guidance: The hyperhidrotic area to be injected may be defined by using standard staining techniques, e.g. MinorĀ“s iodine-starch test.

Recommended dose: 50 Units of botulinum toxin type A is injected intradermally to each axilla, evenly distributed in multiple sites approximately 1-2 cm apart.

The recommended injection volume for intradermal injection is 0.1-0.2 ml.

Maximum dose: Doses other than 50 Units per axilla cannot be recommended.

Additional information: Clinical improvement generally occurs within the first week after injection and persists for 4-7 months.

Repeat injection of botulinum toxin type A can be administered when the clinical effect of a previous injection diminishes and the treating physician deems it necessary. Injections should not be repeated more frequently than every 16 weeks.

Dosage considerations

The maximum cumulative dose should not exceed 400 Units in a 12-week interval.

Active ingredient

Botulinum toxin type A is a protein complex derived from Clostridium botulinum. The protein consists of type A neurotoxin and several other proteins. Under physiological conditions it is presumed that the complex dissociates and releases the pure neurotoxin. Intramuscular injection of the neurotoxin complex blocks cholinergic transport at the neuromuscular junction by preventing the release of acetylcholine. The nerve endings of the neuromuscular junction no longer respond to nerve impulses and secretion of the chemotransmitter is prevented (chemical denervation).

Read more about Botulinum toxin type A

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner